Research Associate I/II, Formulation Development
Boost your chances before you apply.
Arcturus Therapeutics Inc
San Diego, CA, US
Summary
The Research Associate will support the scale-up, manufacturing, and characterization of lipid nanoparticle-based nucleic acid formulations. They are responsible for conducting process development, performing stability studies, and maintaining accurate documentation of all experimental procedures.
Job Description
WHY WORK FOR ARCTURUS?
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global, late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III, and hepatitis B virus. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led to collaborations including, amongst others, Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., and the Cystic Fibrosis Foundation.
Arcturus Therapeutics is presently recruiting outstanding candidates with experience in the field of mRNA technologies and nanoparticle sciences. Our corporate culture is dynamic, diverse, and creative. We value collaboration and teamwork. We seek individuals to join us with a genuine passion for the science behind helping to cure disease and improve the lives of patients.
THE OPPORTUNITY
We are seeking a temporary Research Associate I/II to join our Formulation Team at our Headquarters in San Diego, CA.
In this role, you will support scale-up, manufacturing, and characterization of lipid nanoparticle-based nucleic acid formulations to support our emerging research pipeline. Our ideal candidate will bring a willingness to learn and contribute to our formulation production and purification processes.
WHAT YOU WILL CONTRIBUTE
- Develop nucleic based formulations including complex nanoparticle formulations to support in vitro and in vivo studies for different programs.
- Conduct process development of mRNA-LNP drug product to enable successful production of large-scale drug product in internal and external manufacturing sites.
- Perform process-related investigations, identify root causes of process/manufacturing discrepancies, evaluate systems for trends and adverse findings, and implement appropriate steps to ensure process robustness.
- Perform formulation stability studies, contact material compatibility, in-use compatibility study, and accelerated stability studies.
- Maintain proper documentation of all experimental procedures and results, including batch records, protocols, Standard Operating Procedures (SOPs) and other manufacturing related documentations.
- Prepare technical reports and presentations which summarize procedures, study results, and data interpretation as needed.
- Deliver high quality results in an accurate and a time sensitive manner
- Perform other activities as needed.
WHAT WE SEEK
- 2+ years of relevant formulation development experience in a life science, pharmaceutical company, or academic lab setting. Experience with nucleic acid-based and/or lipid nanoparticle formulation development is a major plus.
- Hands on experience working with liquid, frozen, and/or lyophilized dosage forms and related biophysical and chemical analytical methods such as dynamic light scattering.
- Experience with TFF (Tangential Flow Filtration), dead-end filtration, and/or fill/finish is a plus.
- Record experiments and results in laboratory notebooks (including all electronic systems) in accordance with lab procedures in sufficient detail that co-worker can repeat experiment and interpret results in a timely manner
- Attention to details, ability to think ahead and strong communication skills
- Self-motivated team player excels in a highly innovative, collaborative, and fast-paced environment.
EDUCATION
- Bachelor's or Master’s degree in Chemistry, Pharmaceutical Sciences, Biochemistry, Chemical Engineering, Bioengineering or other related science field
WHAT WE OFFER
- Free variety of snacks and beverages
- On Campus Gym
- Company sponsored FUN events
The anticipated hourly rate for candidates who will work in San Diego is
RA I $34-$45
RA II $39- $52.39
The range provided is based on what we believe is a reasonable estimate for the base salary pay range for this job at the time of posting. The final salary offered to a successful candidate will be dependent on several factors that may include but are not limited to the type and length of experience within the job, type and length of experience within the industry, education, etc. Arcturus Therapeutics is multi state employer and this salary range may not reflect positions that work in other states. Some roles may also be eligible for overtime pay, in accordance with federal and state requirements.
For a deeper dive into our company and corporate culture visit www.ArcturusRx.com
Arcturus is committed to equal employment opportunity and non-discrimination for all employees and qualified applicants without regard to a person's race, color, sex, gender identity or expression, age, religion, national origin, ancestry, ethnicity, disability, veteran status, genetic information, sexual orientation, marital status, or any characteristic protected under applicable law.
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.
Founded
2013
Company size
51-200 employees
Industry
Biotechnology Research
Org type
Public Company
Headquarters
San Diego, California
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration with CSL Seqirus, U.S. BARDA for pandemic flu and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat cystic fibrosis (CF) and ornithine transcarbamylase (OTC) deficiency along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA (siRNA), circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 500 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. Please connect with us on X and LinkedIn.
Founded
2013
Company size
51-200 employees
Industry
Biotechnology Research
Org type
Public Company
Headquarters
San Diego, California